Location History:
- London, GB (2001 - 2007)
- Enfield, GB (2012)
- Hoddesdon Herts, GB (2013)
Company Filing History:
4 out of 2,405 
1 out of 4,770 
1 out of 35 Years Active: 2001-2013
Title: Robert Darrin Wilson: An Innovative Mind in Pharmaceutical Science
Introduction
Robert Darrin Wilson, a distinguished inventor based in London, GB, has made significant contributions to the field of pharmaceutical science, holding an impressive five patents. His work primarily focuses on developing novel compounds that target critical pathways in cancer treatment and other medical applications.
Latest Patents
Among his latest patents, Wilson has developed pharmaceutically acceptable salts of an amide substituted indazole serving as inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP). These compounds are designed as potential mono-therapies for tumors featuring specific DNA-repair defects. Furthermore, they enhance the efficacy of DNA-damaging agents, like anticancer drugs and radiotherapy. Additionally, Wilson has patented a process for the preparation of tetrazolytetrahydrocyclopentapyrazoles, which are useful in various pharmaceutical applications.
Career Highlights
Throughout his career, Wilson has worked with esteemed companies, notably Merck Sharp & Dohme Corporation and Merck Sharpe & Dohme Corp., where he has honed his expertise in drug development and innovation in therapeutics. His dedication to advancing medical science is evident in his patent portfolio, reflecting his ability to innovate continually in the pharmaceutical industry.
Collaborations
Wilson has collaborated with notable individuals in the field, including colleagues David Hands and Ian Frank Cottrell. These partnerships have undoubtedly contributed to the success and impact of his inventive work, showcasing the importance of teamwork in scientific research and development.
Conclusion
Robert Darrin Wilson stands out as an influential figure in the realm of pharmaceutical innovations. His patents not only represent significant advancements in cancer therapy but also highlight his commitment to improving patient outcomes. As he continues to explore new avenues for drug development, the pharmaceutical community eagerly anticipates his future contributions.